Premium Ipamorelin 2mg
-550x550.png)



-80x80.png)



- Stock: In Stock
- Model: EU-IPAM-2mg
- JAN: Pink top
Premium Ipamorelin 2mg - Produced in the EU
Ipamorelin (INN) (developmental code name NNC 26-0161) is a peptide selective agonist of the ghrelin/growth hormone secretagogue receptor (GHS) and a growth hormone secretagogue.[2][3] It is a pentapeptide with the amino acid sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2 that was derived from GHRP-1.[4]
Ipamorelin significantly increases plasma growth hormone (GH) levels in both animals and humans.[1][3][5] In addition, ipamorelin stimulates body weight gain in animals.[5] Like pralmorelin and GHRP-6, ipamorelin does not affect prolactin, follicle-stimulating hormone (FSH), luteinizing hormone (LH), or thyroid-stimulating hormone (TSH) levels.[3] However, unlike pralmorelin (GHRP-2) and GHRP-6, but similarly to growth hormone-releasing hormone(GHRH), ipamorelin does not stimulate the secretion of adrenocorticotropic hormone (ACTH) or cortisol, and is highly selective for inducing the secretion only of GH.930
Ipamorelin was originally developed by Novo Nordisk, and was investigated in phase II clinical trials by Helsinn Therapeutics for the treatment of postoperative ileus.[6][7]
Source: Wikipedia
InChI Key: | NEHWBYHLYZGBNO-BVEPWEIPSA-N |
---|---|
Molecular Formula: | C38H49N9O5 |
UNII: | Y9M3S784Z6 |
Chemical Names: | |
Molecular Weight: | 711.868 g/mol |
Source: PubChem
Clinical Trials:
Ipamorelin has been investigated for the treatment of Ileus:
CTID | Title | Phase | Status | Date |
---|---|---|---|---|
NCT00672074 | Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus | 2 | Completed | 2017-04-12 |
NCT01280344 | Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function | 2 | Completed | 2017-04-12 |
Source: PubChem
Usage:
Product is prepared for LABORATORY RESEARCH USE ONLY. The product may not be used for other purposes.
References:
- Gobburu, Jogarao V. S.; Agersø, Henrik; Jusko, William J.; Ynddal, Lars (1999). "Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin, a Growth Hormone Releasing Peptide, in Human Volunteers". Pharmaceutical Research. 16 (9): 1412–1416. doi:10.1023/A:1018955126402. ISSN 0724-8741.
- ^ Moulin, Aline; Ryan, Joanne; Martinez, Jean; Fehrentz, Jean-Alain (2007). "Recent Developments in Ghrelin Receptor Ligands". ChemMedChem. 2 (9): 1242–1259. doi:10.1002/cmdc.200700015. ISSN 1860-7179. PMID 17520591.
- ^ Jump up to:a b c d Raun, K; Hansen, B.; Johansen, N.; Thogersen, H; Madsen, K; Ankersen, M; Andersen, P. (1998). "Ipamorelin, the first selective growth hormone secretagogue". European Journal of Endocrinology. 139 (5): 552–561. doi:10.1530/eje.0.1390552. ISSN 0804-4643.
- ^ Isidro, Maria; Cordido, Fernando (2006). "Growth Hormone Secretagogues". Combinatorial Chemistry & High Throughput Screening. 9 (3): 175–180. doi:10.2174/138620706776055458. ISSN 1386-2073.
- ^ Jump up to:a b Estrada, R. Cañete; Jiménez-Reina, L.; de la Torre, M.J.; Bernal, J. (2002). "Chronic In Vivo Ipamorelin Treatment Stimulates Body Weight Gain and Growth Hormone (GH) Release In Vitro in Young Female Rats". 6 (1): 37–46. ISSN 1136-4890.
- ^ Beck, David E.; Sweeney, W. Brian; McCarter, Martin D. (2014). "Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients". International Journal of Colorectal Disease. 29 (12): 1527–1534. doi:10.1007/s00384-014-2030-8. ISSN 0179-1958.
- ^ AdisInsight. "Ipamorelin". Retrieved 10 June 2015.